

Solid Tumors

**A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors**

**Trial Status**  
Terminated

**Trial Runs In**  
6 Countries

**Trial Identifier**  
NCT05129280 2021-000624-35  
BE43244

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy dose-escalation and dose expansion study of RO7444973. The aim of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RO7444973 in participants with unresectable and/or metastatic melanoma-associated antigen A4 (MAGE-A4)-positive, solid tumors, carrying the HLA-A\*02:01 allele.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT05129280 2021-000624-35 BE43244**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---